



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: THOMPSON ET AL. Examiner: UNKNOWN
Serial No.: 10/717,163 Group Art Unit: UNKNOWN
Filed: NOVEMBER 18, 2003 Docket: X-11441US/13903.4USD1
Confirmation No.: UNKNOWN
Due Date: FEBRUARY 18, 2004
Title: N¹-MODIFIED GLYCOPEPTIDES

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, ~~VA 22313-1450~~ on February 18, 2004.

By: 

Name: Tracy D. Vuemanich

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

23552

PATENT TRADEMARK OFFICE

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal Sheet in duplicate containing Certificate of Mailing
- ☒ Information Disclosure Statement, Form 1449
- ☒ Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers or any future reply, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

MERCHANT & GOULD P.C.
P.O. Box 2903, Minneapolis, MN 55402-0903
612.332.5300

By: 

Name: Anna M. Nelson

Reg. No.: 48,935

ANelson:PLStov



S/N 10/717,163

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	THOMPSON ET AL.	Examiner:	UNKNOWN
Serial No.:	10/717,163	Group Art Unit:	UNKNOWN
Filed:	NOVEMBER 18, 2003	Docket No.:	X-11441US/13903.4USD1
Title:	N ¹ -MODIFIED GLYCOPEPTIDES		

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on February 18, 2004.

By: 

Name: Tracy Ojeda-Vucenich

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted within three months of the filing date of the above-identified application, which is not an application under 37 C.F.R. § 1.53(d). Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. § 1.98(d), a copy of each document or other information listed on the enclosed Form 1449 is not provided because it was previously cited by or submitted to the U.S. Patent and Trademark Office in parent application, U.S. Serial No. 09/647,113 filed on September 26, 2000, now U.S. Patent No. 6,670,446 B1.

In accordance with 37 C.F.R. § 1.98(a)(2)(i), a copy of the U.S. Patent No. 6,670,446 B1 listed on the enclosed Form 1449 is not provided, as this application was filed after June 30, 2003.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to

establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.


Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Date: February 18, 2004

Anna M. Nelson
Anna M. Nelson
Reg. No. 48,935
AMN:PLStov



FORM 1449* 	INFORMATION DISCLOSURE STATEMENT	
	IN AN APPLICATION	
	(Use several sheets if necessary)	
Docket Number: X-11441US/13903.4USD1	Application Number: 10/717,163	
Applicant: THOMPSON ET AL.		
Filing Date: 11/18/2003	Group Art Unit: UNKNOWN	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,639,433	01/27/1987	Hunt et al.			
	4,643,987	02/17/1987	Nagarajan et al.			
	4,698,327	10/06/1987	Nagarajan et al.			
	5,312,738	05/17/1994	Hamill et al.			
	5,534,420	07/09/1996	Debono et al.			
	5,591,714	01/07/1997	Nagarajan et al.			
	6,670,446 B1	12/30/2003	Thompson et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	435503A1	07/03/1991	EP				
	435503B1	07/03/1991	EP				
	667353A1	08/16/1995	EP				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Allen, N. et al., "Hexapeptide Derivatives of Glycopeptide Antibiotics: Tools for Mechanism of Action Studies," <i>Antimicrobial Agents and Chemotherapy</i> , Vol. 46, No. 8, pp. 2344-2348 (August 2002).
	Booth et al., <i>J. Chem. Soc., Chem. Commun.</i> , pp. 1694-1695 (1987)
	Cristofaro et al., <i>J. Antibiotics</i> , Vol. 48, pp. 805-810 (1995)
	Gorlitzer et al., <i>J. Chem. Soc., Perkins Trans. 1</i> , pp. 3253-3257 (1999)
	Harris, C. et al., "The Role of the Chlorine Substituents in the Antibiotic Vancomycin: Preparation and Characterization of Mono- and Didechlorovancomycin," <i>J. Am. Chem. Soc.</i> , Vol. 107, pp. 6652-6658 (1985).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: X-11441US/13903.4USD1	Application Number: 10/717,163
	Applicant: THOMPSON ET AL.	
	Filing Date: 11/18/2003	Group Art Unit: UNKNOWN

		Kannan, R. et al., "Function of the Amino Sugar and N-Terminal Amino Acid of the Antibiotic Vancomycin in Its Complexation with Cell Wall Peptides," <i>J. Am. Chem. Soc.</i> , Vol. 110, pp. 2946-2953 (1988).
		Mackay, J. et al., "Glycopeptide Antibiotic Activity and the Possible Role of Dimerization: A Model for Biological Signaling," <i>J. Am. Chem. Soc.</i> , Vol. 116, pp. 4581-4590 (1994).
		Miroshnikova et al., <i>J. Antibiotics</i> , Vol. 49, pp. 1157-1161 (1996)
		Nagarajan et al., <i>J. Chem. Soc., Chem. Commun.</i> , pp. 1306-1307 (1988)
		Nagarajan, <i>J. Antibiotics</i> , Vol. 46, pp. 1181-1195 (1993)
		Nicas et al., <i>Antimicrobial Agents and Chemotherapy</i> , Vol. 33, No. 9, pp. 1477-1481 (1989)
		Walsh, C.T. et al., "Bacterial Resistance to Vancomycin: Five Genes and One Missing Hydrogen Bond Tell the Story," <i>Chemistry & Biology</i> , Vol. 3, No. 1, pp. 21-28 (January 1996).
		Zmijewski et al., <i>J. Natural Products</i> , Vol. 52, pp. 203-206 (1989)

23552

PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	